RxDoctor Payments Data

Ethan Myers

Family · New Hartford, NYNPI 1851952675

Payments from drug & device makers

$10,229in general payments, 2019–2025

Across 577 payments — averaging $17.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Pfizer$880
  • AstraZeneca$563
  • Lilly USA, LLC$533
  • Amgen$467
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$440
  • plus $5K from 37 others

What the payments were for

  • Food & beverage$10,229100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,229 in reported general payments places this provider in the 95th percentile of 8,883 family providers in New York.

See all family providers in New York

Medicare billing

Part B allowed, 2024
$22,398
Medicare patients
57
Services billed
380

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide41$41,812
Trelegy ElliptaFluticasone/Umeclidin/Vilanter62$40,982
EliquisApixaban44$35,555
JanuviaSitagliptin Phosphate37$32,365
JardianceEmpagliflozin39$27,011
VascepaIcosapent Ethyl35$21,341
VraylarCariprazine Hcl14$19,749
FarxigaDapagliflozin Propanediol17$17,969
BelbucaBuprenorphine Hcl27$17,055
XareltoRivaroxaban19$16,888
MounjaroTirzepatide16$16,451
KerendiaFinerenone23$14,930
BrixadiBuprenorphine13$14,432
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl164$13,769
Nurtec OdtRimegepant Sulfate12$13,672

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Nurtec Odt$880$49,22656 claims
GSKTrelegy Ellipta, Incruse Ellipta$157$45,70473 claims
Novo NordiskOzempic$249$41,81241 claims
Boehringer IngelheimJardiance, Tradjenta$302$39,53858 claims
MerckJanuvia$239$32,36537 claims
AbbVieVraylar$2,453$19,74914 claims
AstraZenecaFarxiga$563$17,96917 claims
Collegium Pharmaceutical, Inc.Belbuca$291$17,05527 claims
Johnson & JohnsonXarelto$162$16,88819 claims
Lilly USA, LLCMounjaro$533$16,45116 claims
BayerKerendia$220$14,93023 claims
Braeburn Inc.Brixadi$399$14,43213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,883 family providers in New York.

Other family in New Hartford

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →